Device measures memory loss, brain functioning
May 15, 2019
MONTREAL – Thought Technology is pleased to announce a joint distribution agreement with Evoke Neuroscience for its eVox System, a medical device that enables primary and specialty care physicians to assess brain function in-office and use the results to aid in making a clinical diagnosis.
Marinela Gombosev (pictured), Chief Executive Officer at Evoke Neuroscience said, “To date, the eVox System has been used to measure the brain health of over 48,000 patients in primary care clinics and specialty practice settings in the United States. eVox adds significant value to clinical practices because it offers doctors the opportunity to implement early interventions to reduce risk of cognitive impairment, Alzheimer’s, and other dementias by aiding doctors in diagnosis of memory loss and other cognitive disorders.”
Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox System delivers objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as Alzheimer’s and other dementias.
Primary and specialty care physicians can use eVox to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox System is appropriate to aid in diagnosis.
eVox uses electroencephalography (EEG) to reveal biomarkers of physiological aging and memory performance. This can allow for early detection of memory loss and MCI. Plus, eVox measures Event-Related Potentials (ERPs), which reflect brain processing speed for cognitive processes like decision making, attention, and memory. ERP testing can reveal early risk measures of dementia.
“The eVox System is a wonderful addition to our product line and our collaboration with Evoke Neuroscience will allow Thought Technology to expand its assessment and training solutions to customers who are interested in using Quantitative EEG prior to trainings,” said Helen Mavros, Director of Sales and Marketing at Thought Technology.
About Thought Technology Ltd.
Founded in 1975, Thought Technology is the world’s leading biofeedback and physiological instrument manufacturer. Its products are used as an essential part of many therapeutic treatments and clinical assessment protocols in over 85 countries and are used by tens of thousands of clinicians in thousands of medical institutions. Always supportive of new research and development ideas, Thought Technology Ltd. has encouraged a number of special interest groups and clinicians to create cutting edge applications for its instrumentation. Thought Technology Ltd. equipment is now being used in telemedicine, web-based monitoring and biofeedback, sports training, research in human-machine interface, physiology-driven multimedia environments and virtual reality. Constantly striving to improve the quality of the products and services, TTL has obtained, and maintains, ISO 13485, and CE certification for the organization and products.
About Evoke Neuroscience, Inc.
Evoke Neuroscience was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful, and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.